Characterization of common CYP1B1 variants with different capacity for benzo[a] pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene

被引:43
作者
Aklillu, E
Ovrebo, S
Botnen, IV
Otter, C
Ingelman-Sundberg, M
机构
[1] Karolinska Univ Hosp Huddinge, Div Clin Pharmacol, Dept Lab Med, SE-14186 Stockholm, Sweden
[2] Karolinska Inst, Inst Environm Med, Div Mol Toxicol, Stockholm, Sweden
[3] Natl Inst Occupat Hlth, Dept Toxicol, Oslo, Norway
[4] AstraZeneca Molndal R&D, Mol Biol, Molndal, Sweden
关键词
D O I
10.1158/0008-5472.CAN-05-0113
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cytochrome P450 1B1 (CYP1B1), an extrahepatic enzyme inducible by smoking, is overexpressed in many tumors and catalyzes the metabolic activation of procarcinogens such as polycyclic aromatic hydrocarbons. In human, CYP1B1 is genetically polymorphic and five common missense mutations causing amino acid substitution have been identified. In this study, we have investigated CYP1B1 haplotypes present in a Spanish population and carried out functional analyses of the corresponding enzymes in yeast using benzo[a]pyrene as a substrate. CYP1B1*1, CYP1B1*2, CYP1B1*3, CYP1B1*4, CYP1B1*6, and CYP1B1*7, encoding combinations of the Arg48Gly, Ala119Ser, Leu432Val, Asn453Ser, and Ala443Gly amino acid substitutions, were present at frequencies of 14.3%, 25.5%, 38.8%, 18.1%, 0.4%, and 2.6%, respectively. The variant CYP1B1 forms were heterologously expressed with human reductase in Saccharomyces cerevisiae and kinetic analyses of benzo[a]pyrene metabolism were carried out. CYP1B1.7, having the amino acid substitutions Arg48Gly, Ala119Ser, Leu432Val, and Ala443Gly, exhibited a significantly decreased capacity (P < 0.001) for the formation of (+/-)-benzo[a]pyrene-trans-7,8-dihydrodiol from benzo[a]pyrene as indicated by lower intrinsic clearance (V-max/K-m). A somewhat decreased clearance was observed for CYP1B1.4, whereas no significant differences in kinetic properties among the remaining variant enzymes were observed as compared with CY-P1B1.1. Thus, genetic polymorphism in the CYP1B1 gene, as defined by the haplotypes investigated, might cause interindividual differences in susceptibility (e.g., to lung cancer induced by smoking). The results indicate the necessity to make molecular epidemiologic investigations regarding the association of the specific CYP1B1 haplotypes and cancer risk.
引用
收藏
页码:5105 / 5111
页数:7
相关论文
共 48 条
[1]   Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population [J].
Aklillu, E ;
Oscarson, M ;
Hidestrand, M ;
Leidvik, B ;
Otter, C ;
Ingelman-Sundberg, M .
MOLECULAR PHARMACOLOGY, 2002, 61 (03) :586-594
[2]  
Bailey LR, 1998, CANCER RES, V58, P5038
[3]   Proteasomal degradation of human CYP1B1: Effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression [J].
Bandiera, S ;
Weidlich, S ;
Harth, V ;
Broede, P ;
Friedberg, T .
MOLECULAR PHARMACOLOGY, 2005, 67 (02) :435-443
[4]   DNA adducts in human carcinogenesis: Etiological relevance and structure-activity relationship [J].
Bartsch, H .
MUTATION RESEARCH-REVIEWS IN GENETIC TOXICOLOGY, 1996, 340 (2-3) :67-79
[5]   Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia [J].
Bejjani, BA ;
Lewis, RA ;
Tomey, KF ;
Anderson, KL ;
Dueker, DK ;
Jabak, M ;
Astle, WF ;
Otterud, B ;
Leppert, M ;
Lupski, JR .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (02) :325-333
[6]   Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas [J].
Buters, JTM ;
Sakai, S ;
Richter, T ;
Pineau, T ;
Alexander, DL ;
Savas, U ;
Doehmer, J ;
Ward, JM ;
Jefcoate, CR ;
Gonzalez, FJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) :1977-1982
[7]   Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer [J].
Chang, BL ;
Zheng, SL ;
Isaacs, SD ;
Turner, AR ;
Hawkins, GA ;
Wiley, KE ;
Bleecker, ER ;
Walsh, PC ;
Meyers, DA ;
Isaacs, WB ;
Xu, J .
BRITISH JOURNAL OF CANCER, 2003, 89 (08) :1524-1529
[8]  
Chen H, 2000, DRUG METAB DISPOS, V28, P315
[9]   Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53 [J].
Denissenko, MF ;
Pao, A ;
Tang, MS ;
Pfeifer, GP .
SCIENCE, 1996, 274 (5286) :430-432
[10]  
Goodman MT, 2001, CANCER EPIDEM BIOMAR, V10, P209